VRNA

Verona Pharma Plc

NASDAQ

Add Alert

VRNA

Verona Pharma Plc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Hoskuld

09/13/24 5:06 PM

Post #213

Re: #212: @gbrown6332 - Saw your original post on VRNA. Sounded

That is great GB!

gbrown6332

09/12/24 9:52 PM

Post #212

Re: #202: @Hoskuld - Just following up on this...I can see ohtuvayre

Saw your original post on VRNA. Sounded good. Decided to tag along. Glad I did.

Thks,

G. Brown

powerwalker

08/23/24 4:12 PM

Post #211

Someone certainly does not want this stock to go and stay above $28.

Bullish

Hoskuld

08/18/24 10:13 AM

Post #209

Re: #207: @Roger1 - Checked out the drug with CVS and was

Got it - you meant pharmacies not pharmas (which are drug manufacturing companies.) Makes sense. I will actually check to see if ohtuvayre is at local CVS this week!

I can imagine you would be excited about this and I am really looking forward to hearing about your experience with it! Thanks for sharing!

Roger1

08/18/24 9:20 AM

Post #208

Re: #207: @Roger1 - Checked out the drug with CVS and was

Btw, I didn't say it wasn't going well. I said it takes time for any new drug given the logistics. I think they're doing a great job or i wouldn't have invested in them.

Roger1

08/18/24 9:11 AM

Post #207

Re: #206: @Hoskuld - They were already detailing 100 of the top

Checked out the drug with CVS and was told about specialty pharmas. I'm a COPD patient and respiratory therapist and have followed trials for quite a while and am delighted to try this drug. Was told the same thing by Verona when I signed up for the drug through the patient portal. I used to teach the mechanism of action of bronchodilators. Specifically C3-5AMP . Taught therapists, nurses, and many of the older physicians sat in for refresher.
Check with your pharmacist and see if it's available. I'd be interested in your findings.

Hoskuld

08/18/24 8:11 AM

Post #206

Re: #205: @Roger1 - I think it will be January b4 the

They were already detailing 100 of the top 2,500 pulmonologists as of 2 weeks ago, and presumably are detailing ~20-25 more each week. The launch is already going well.

What did you mean by "speciality pharmas until then"?

Roger1

08/17/24 9:37 PM

Post #205

Re: #203: @powerwalker - Hoskuld, I listened to the quarterly cc and

I think it will be January b4 the roll out is complete. Specialty pharmas until then. Have patience, this drug will be a blockbuster with its double mechanism of action.

Hoskuld

08/17/24 11:29 AM

Post #204

Re: #203: @powerwalker - Hoskuld, I listened to the quarterly cc and

Hi PW - the company has said that they are looking to partner ohtuvayre in the EU and, as a part of that partnership, the partner would be responsible for developing an inhaler for ohtuvayre, too.

I agree that the company management seems sharp. And all newly launched products have issues - let's hope Verona is on top of the issues. I wrote IR and simply asked that they send me a note saying that my message was received and the responsible people at Verona are "on it".

powerwalker

08/17/24 8:44 AM

Post #203

Re: #201: @Hoskuld - A couple of pulmonologists on stocktwits describe issues

Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.

Hoping the patient numbers are higher within a year.

Have you seen or heard any info on EMA and/or UK filings/approval?

Bullish

Hoskuld

08/17/24 8:16 AM

Post #202

Re: #201: @Hoskuld - A couple of pulmonologists on stocktwits describe issues

Just following up on this...I can see ohtuvayre being the SOC. I think this will grow very, very swiftly.

Hoskuld

08/16/24 9:33 PM

Post #201

A couple of pulmonologists on stocktwits describe issues with scripts that they have written being fulfilled. On the other hand, one of the pulmonologists is writing 5-6 scripts per day and the other seemed to be writing 2 per day. 5-6 per day = 1,000+ per year for one high-prescribing pulmonologist. And ~400 for a less aggressive prescriber. To me, those seem like promising numbers and point to hitting 60,000+ plus patients over the next year as being probable and NOT a stretch.

Hoskuld

08/14/24 5:04 PM

Post #200

Re: #199: @powerwalker - Not actually a "Hit" piece, but leaves negative

Luckily, we know the story here.

powerwalker

08/14/24 10:15 AM

Post #199

Not actually a "Hit" piece, but leaves negative impressions, anyway. Released earlier in late July ... must not have had the intended effect, so it tries again.

Top 3 Health Care Stocks That May Crash In August

https://www.benzinga.com/news/24/08/40365322/top-3-health-care-stocks-that-may-crash-in-august

Bullish

Hoskuld

08/13/24 10:56 PM

Post #198

Re: #197: @k9uwa - Hope everyone is buckled in and enjoying the

Glad you are making money here k9uwa! I think we will see this go much higher over the next couple of years. Would really like to get access to script data...

k9uwa

08/13/24 4:04 PM

Post #197

Re: #196: @Hoskuld - Anyone have IMS / IQVIA script data access

Hope everyone is buckled in and enjoying the ride. I Am Wishing I had put another zero onto my purchase on this one.
Thanks U and Guzzie
John k9uwa

Bullish

Hoskuld

08/13/24 11:59 AM

Post #196

Anyone have IMS / IQVIA script data access for Ohtuvayre? Has been a few weeks and this is doing exactly what it should do. Hope everyone is buckled in and enjoying the ride.

Golden Cross

06/27/24 10:39 AM

Post #195

$VRNA COPD drug approved
- 1st-in-class neb PDE4 inhibitor
- antinflamm + b-dilator
- Clean, broad label, no restrictions
- Complements ICS LABA LAMA, doesn't compete
- Targets broad COPD population vs. narrow biologics like Dupixent
- Big Pharma (Boehringer, GSK) easy bolt-on addition to pipeline

Bullish

Golden Cross

06/26/24 6:18 PM

Post #194

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)https://t.co/6gOmzKSwx2
— 💸 Golden Cross Stocks 💸 (@CrossStocks) June 26, 2024

Bullish

HMB2010

06/26/24 5:35 PM

Post #193

Re: #192: @stock1ace1 - Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize ensifentrine in Greater China. On April 6th 2023, Nuance Pharma announced first patient in (FPI) for the ENHANCE-China Phase III clinical trial.

https://finance.yahoo.com/news/nuance-pharmas-partner-verona-pharma-090700900.html

Should be good return here!

stock1ace1

06/26/24 5:31 PM

Post #192

Re: #191: @Golden Cross - so is the price already figured in or

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine

Golden Cross

06/25/24 6:45 PM

Post #191

so is the price already figured in or what here

Golden Cross

06/25/24 3:17 PM

Post #190

$VRNA awaits FDA decision on June 26 for ensifentrine, a groundbreaking COPD therapy. With $901.89M in cash, they’re set for a strong future. Approval could make ensifentrine the first new inhaled #COPD treatment in 20+ years!

PonkenPlonken

06/03/24 8:58 AM

Post #189

Today, we have entered into two strategic financing agreements with Oaktree and OMERS, providing access to up to $650M to support the potential US launch of #ensifentrine and the expansion of its clinical activities.
Read more here: https://t.co/vF5GOXjXtN $VRNA pic.twitter.com/pRMLsHPe0t
— Verona Pharma (@VeronaPharma) May 9, 2024

this does not look like Ensifentrine is expected to fail.

Amatuer17

04/16/23 7:57 PM

Post #188

https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air

Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.

Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.

4Godnwv

02/01/23 7:25 PM

Post #187

Great news today AH - this little pharm might be going places.

TheFinalCD

12/30/22 3:11 PM

Post #186

Re: #180: @TheFinalCD - 17.77

25.77

Bullish

Amatuer17

12/30/22 1:23 PM

Post #185

Re: #184: @Laster - Very few sure bets on Nasdaq.

COPD is a crowded place - not sure about what is special about their drug?

Unless this drug is better than other COPD drugs - this co is fully priced @ $2 B

This co cannot market the product even if approved - so it needs to be bought out but it will not get more than $3 B - so maybe 50% premium from here

Laster

12/30/22 12:18 PM

Post #184

Re: #183: @TheFinalCD - $23's

Very few sure bets on Nasdaq.
But I think it is a safe bet that this company will be bought out in 2023. Significantly high stock price.
Patience will pay off here.
JMO.

TheFinalCD

12/21/22 5:05 PM

Post #183

Re: #181: @BottomBounce - $VRNA Has $5.83M DEBT

$23's

Bullish

Zadie420

12/21/22 8:21 AM

Post #182

Re: #181: @BottomBounce - $VRNA Has $5.83M DEBT

Which one does not have debt? Really!!!!!!

$5.8 Mil is peanuts compare to other companies. Next time read before you posted.

BottomBounce

12/20/22 2:32 PM

Post #181

$VRNA Has $5.83M DEBT

Bearish

TheFinalCD

12/20/22 8:49 AM

Post #180

Re: #175: @georgie18 - VRNA...$6.91...Looking for a strong bouncer on the Gap

17.77

TheFinalCD

12/20/22 8:32 AM

Post #179

Re: #177: @crudeoil24 - Verona Pharma Announces Proposed Underwritten Public Offering Of

https://finviz.com/quote.ashx?t=VRNA&p=d

Bullish

TheFinalCD

12/20/22 8:31 AM

Post #178

Re: #172: @Pyramid2 - Congrats to all that Traded this one today!

NEWS https://finance.yahoo.com/news/verona-pharma-announces-ensifentrine-meets-070000223.html

crudeoil24

08/09/22 8:26 PM

Post #177

Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

tw0122

08/09/22 8:10 AM

Post #176

Big COPD runner today broke 52 week highs premarket

georgie18

06/19/21 5:48 AM

Post #175

Re: #174: @georgie18 - VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and

VRNA...$6.91...Looking for a strong bouncer on the Gap Fill...imo...we shall see...

Chart...https://schrts.co/SknAkrda ...

georgie18

06/10/21 7:02 AM

Post #174

VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:

ClayTrader

07/17/20 7:21 PM

Post #173

* * $VRNA Video Chart 07-17-2020 * *

Link to Video - click here to watch the technical chart video

Pyramid2

07/17/20 1:36 PM

Post #172

Congrats to all that Traded this one today!

Dubster watching

07/17/20 1:31 PM

Post #171

I’ve move up!
I keep finding these pops

FAGIxDILUTIONxDDMASTER

06/02/20 5:43 PM

Post #170

This thing is moving back to $6 and has a huge potential runway, even analysts are saying $34-$50 a share - I always cut their projections in half especially wedbush (who held 70,000 shares as of march 31st).

That still leaves us with a 5x potential over medium to long term - this thing can dance with news buckle up.

Clemdane

02/26/20 11:45 PM

Post #169

Something's brewing here

PatiencePaysOff79

01/27/20 7:40 PM

Post #168

$VRNA-Someone’s got $150k on the bid at $5.80 a/ha. Something brewing again?

Polebarn

01/16/20 6:53 PM

Post #166

Re: #68: @dinogreeves - Loaded heavy on the dip, nice average now.

This thing at $60 yet?

BAHAHAHAHA....

BoilerRoom

01/15/20 4:18 PM

Post #165

Stop the bleed! Company is obviously diluting shares!!!

BoilerRoom

01/15/20 3:32 PM

Post #164

Calling $3.80 the bottom here.

BoilerRoom

01/15/20 3:08 PM

Post #163

How we doing here today? Green?

TheFinalCD

01/15/20 1:17 PM

Post #162

sub $6

SMH

Older

Verona Pharma Plc (VRNA)

Followers	14	Posters	35
Posts (Today)	0	Posts (Total)	213
Created	12/03/19	Type	Free
Moderators

(VRNA-DD)Market-cap $57 M --Cash $51 M --Shares Out 13.17 M --Great Pipeline -- Strong Insider & Institutional Ownership -- Phase 2b readout of the COPD trial is imminent (during this Q) ,positive results could push this extreme low float stock closer or even above $10 . Unsidocvered and brutally undepriced Stock with massive upside Potential here .GL

Market-Cap $57 M
Cash $51 M
Price $3.90

Shares Out 13.17 M

"We are very pleased that our four-week Phase 2b dose-ranging clinical trial with nebulized ensifentrine is progressing according to plan and that we have completed enrollment of over 400 symptomatic patients with moderate to severe COPD. We anticipate completing this study around the end of 2019."

Presentation (from late November)
https://investors.veronapharma.com/static-files/9ed398c4-3150-4c0e-8fe3-1efe276fbffb

Verona Pharma has compound with 'massive potential to impact lives of COPD and asthma patients'...02.12.2019
https://www.biotech-capital.com/companies/news/908274/verona-pharma-has-compound-with--massive-potential-to-impact-lives-of-copd-and-asthma-patients--908274.html

Insider Buying
https://www.lse.co.uk/DirectorsDeals.asp?shareprice=VRP&share=Verona-Pharma

Top Shareholders :

Vivo Capital, LLC ...1.5M
OrbiMed ...1.3M
New Enterprise ...1.2M
Abingworth ...901.9K
VenBio Partners LLC ...875.0K
Novo Holdings A/S ...740.7K
Andera Partners ...720.9K
Aisling Capital ...443.6K
Tekla Capital ...275.0K
Arctic Fund ...120.4K